Matteo Lambertini, MD PhD· @matteolambe · X·· 21 小时前评分45
正文 · 原文
Oral abstract #BreastCancer session at #ESMO26: very promising data with the bispecific anti-HER2 antibody #anbenitamab plus an experimental taxane #HB1801 as first-line therapy in advanced #HER2+ disease
@OncoAlert @myESMO
54 浏览 · 4 赞 · 4 转发 · 0 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org来源：Matteo Lambertini, MD PhD · x.com